Adriana Tremoulet
University of California, San Diego · Professor
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
2
all conditions, ClinicalTrials.gov
NIH grants tied to them
11
2 more share only the name and are not shown
Trial papers
19
PubMed author-name match
Trials
Studies that name Adriana Tremoulet as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:13 UTC. Open this list on ClinicalTrials.gov
- Ph2/Ph3NCT04898231 · MIS-C Comparative Effectiveness StudyUniversity of California, San Diego · completed · Multisystem Inflammatory Syndrome-Children · principal investigator
- Early Ph1NCT04747847 · Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki DiseaseUniversity of California, San Diego · completed · Kawasaki Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- CTSA K12 Program at University of California San Diego Altman Clinical and Translational Research InstituteK12TR005441 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2025 to 2026 · $1,612,278 awarded in 2026Same name and institution; not confirmed by an ID
- Project 1: ClinicalP50HD106463 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2021 to 2026 · $185,390 awarded in 2026Same name and institution; not confirmed by an ID
- UC San Diego Raising Advancement and Parity for Infectious Disease Researchers (RAPID) Faculty Development ProgramR25AI147376 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2025 to 2026 · $378,762 awarded in 2026Same name and institution; not confirmed by an ID
- Academic Training in Therapeutic Advancement for Child Health (ATTACH)T32HD087978 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2016 to 2025 · $189,669 awarded in 2025Same name and institution; not confirmed by an ID
- 14th Annual International Kawasaki Disease Symposium 2024R13HL174111 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2024 · $7,500 awarded in 2024Same name and institution; not confirmed by an ID
- Diagnosing and predicting risk in children with SARS-CoV-2- related illnessR33HD105590 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2023 · $410,937 awarded in 2023Same name and institution; not confirmed by an ID
- Innate Immune Activation and Endothelial Cell Dysfunction in Acute Kawasaki DiseaseR01HL140898 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2018 to 2022 · $729,091 awarded in 2022Grant number is on one of their registry trials
- Pediatric and Developmental Pharmacology for Inflammatory and Infectious DiseasesP50HD090259 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2019 to 2020 · $711,940 awarded in 2020Same name and institution; not confirmed by an ID
- Pediatric and Developmental Pharmacology for Inflammatory and Infectious DiseasesU54HD090259 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2016 to 2018 · $734,233 awarded in 2018Same name and institution; not confirmed by an ID
- Phase I and IIa trial of atorvastatin in children with acute Kawasaki diseaseR01HD081296 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2014 to 2017 · $300,795 awarded in 2017Same name and institution; not confirmed by an ID
- Pharmacologic Determinants for Optimized Therapy in HIV-Infected ChildrenK23HD056939 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2007 to 2011 · $121,770 awarded in 2011Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:13 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- 233 citationsRCR 9.1
- Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.J Pediatr · 2011132 citationsRCR 5.0
- miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease.Circ Res · 2017107 citationsRCR 4.0
- Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.Lancet Child Adolesc Health · 202185 citationsRCR 5.5
- Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design.Antimicrob Agents Chemother · 201462 citationsRCR 2.9
- Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).Contemp Clin Trials · 201658 citationsRCR 2.1
- Specificity of regulatory T cells that modulate vascular inflammation.Autoimmunity · 201455 citationsRCR 1.7
- Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial.J Pediatr · 202241 citationsRCR 3.8
- Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.Clin Exp Immunol · 201339 citationsRCR 1.2
- Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.J Pediatr · 201929 citationsRCR 1.4